On April 24, 2026, researchers at the University Medical Center Groningen (UMCG) announced the initiation of the first-in-human clinical trial for a novel oral compound, designated GR-2023, targeting motor symptom progression in early-stage Parkinson’s disease. This Groningen-developed pill, born from a decade-long investigation into hibernation-induced neuroprotection observed in European hamsters, aims to modulate mitochondrial dysfunction and alpha-synuclein aggregation—two core pathophysiological drivers of Parkinson’s neurodegeneration. The Phase I/IIa trial, currently recruiting 60 participants across the Netherlands, represents a significant step toward disease-modifying therapy in a condition affecting over 10 million people globally, where existing treatments primarily manage symptoms without halting underlying neuronal loss.
From Hibernation Biology to Human Trials: The Groningen Discovery
The foundation of GR-2023 lies in research led by Professor Rob Henning of UMCG, who identified that winter-hibernating hamsters naturally elevate levels of a specific endogenous peptide that protects neurons from ischemic and oxidative stress during prolonged low-metabolism states. This peptide, later synthesized and optimized as GR-2023, demonstrated in preclinical models the ability to enhance mitophagy—the cellular cleanup of damaged mitochondria—and reduce toxic oligomer formation of alpha-synuclein, the protein whose misfolding characterizes Lewy bodies in Parkinson’s disease. In transgenic mouse models of Parkinson’s, GR-2023 administration over six months resulted in a 40% preservation of dopaminergic neurons in the substantia nigra and significant improvement in motor coordination tests, without observable toxicity at therapeutic doses.
In Plain English: The Clinical Takeaway
- GR-2023 is not a cure but aims to slow Parkinson’s progression by protecting brain cells from internal stress and protein clumping.
- Unlike current dopamine-replacing drugs, this pill targets the root biological mechanisms of neurodegeneration.
- Early trial participants will be closely monitored for safety, with efficacy assessed through standardized movement scales and biomarker tracking.
Clinical Trial Design and Regulatory Pathway
The ongoing trial (NL9876, EU Clinical Trials Register) is a randomized, double-blind, placebo-controlled study enrolling patients aged 50-75 diagnosed with idiopathic Parkinson’s disease within the past two years, Hoehn & Yahr stage I-II, and stable on dopaminergic therapy. Participants receive either GR-2023 or placebo once daily for 12 months, with primary endpoints focused on change in MDS-UPDRS Part III (motor examination) scores and secondary endpoints including dopamine transporter (DaT) SPECT imaging and cerebrospinal fluid levels of neurofilament light chain (NfL), a biomarker of axonal damage. Safety monitoring includes quarterly cardiac ECGs, liver function tests, and neuropsychiatric evaluations, given the peptide’s origin in central nervous system stress-response pathways.
Geopolitically, the trial’s location in the Netherlands positions it under the regulatory oversight of the Central Committee on Research Involving Human Subjects (CCMO) and the Medicines Evaluation Board (CBG-MEB), the Dutch equivalent of the EMA. Should Phase IIb/III trials demonstrate efficacy, GR-2023 would seek centralized authorization through the European Medicines Agency (EMA), potentially offering a new therapeutic avenue within the EU’s healthcare systems, including the NHS in the UK for patients accessing cross-border treatments under specific reimbursement agreements.
Funding, Transparency, and Independent Oversight
The preclinical development and Phase I safety studies of GR-2023 were funded by a combination of regional grants from the Groningen Province Innovation Fund and a Horizon Europe grant (ID: HORIZON-HLTH-2021-STAYHLTH-01-02) awarded to the Translational Neurotherapeutics Consortium, a partnership between UMCG, Leiden University Medical Center, and the German Center for Neurodegenerative Diseases (DZNE). The current Phase I/IIa trial is sponsored by the academic hospital UMCG, with no direct pharmaceutical industry involvement at this stage. To mitigate perceived bias, an independent Data and Safety Monitoring Board (DSMB), comprising neurologists and statisticians unaffiliated with the research team, oversees interim analyses. Dr. Henning has publicly stated that intellectual property rights for GR-2023 are held by the University of Groningen, ensuring any future commercialization would return value to public research institutions.
“What makes GR-2023 scientifically compelling is its basis in a natural adaptive mechanism—hibernation neuroprotection—that we’ve translated into a molecule targeting fundamental cellular housekeeping processes gone awry in Parkinson’s. We’re not just treating symptoms; we’re testing whether we can bolster the brain’s own resilience.”
— Prof. Rob Henning, PhD, Department of Anesthesiology, University Medical Center Groningen, interview with Nature Neuroscience, March 2026.
“While repurposing endogenous protective pathways is a promising strategy, neurodegenerative trials face high failure rates due to biological complexity. Rigorous, biomarker-driven Phase II studies like this one in Groningen are essential before advancing to larger, costly Phase III programs.”
— Dr. Maria Sanchez, MD, PhD, Senior Neurologist, Alzheimer’s Association Clinical Trials Initiative, commentary in JAMA Neurology, April 2026.
Comparative Overview: GR-2023 in Context
| Attribute | GR-2023 (Groningen Pill) | Standard Parkinson’s Therapy (Levodopa/Carbidopa) | Disease-Modifying Benchmark (e.g., Anti-alpha-synuclein mAb) |
|---|---|---|---|
| Mechanism of Action | Enhances mitophagy; reduces alpha-synuclein oligomerization | Replaces depleted dopamine | Targets extracellular alpha-synuclein aggregates |
| Administration | Oral, once daily | Oral, multiple times daily | Intravenous infusion |
| Primary Goal | Slow neurodegeneration | Alleviate motor symptoms | Slow neurodegeneration |
| Current Trial Phase | Phase I/IIa (safety & preliminary efficacy) | Approved (symptomatic) | Phase II/III (variable results) |
| Key Biomarker Tracked | CSF NfL, DaT-SPECT | Clinical symptom scales | CSF alpha-synuclein, PET imaging |
Contraindications & When to Consult a Doctor
As an investigational agent, GR-2023 is not available outside the clinical trial. Patients with known hypersensitivity to synthetic peptides, severe hepatic impairment (Child-Pugh C), or uncontrolled cardiac arrhythmias were excluded from the trial based on preclinical safety signals. Individuals with a history of psychosis or impulse control disorders should exercise caution, as central nervous system modulation—even with endogenous-like compounds—can rarely exacerbate neuropsychiatric symptoms. Anyone experiencing worsening tremor, new-onset confusion, hallucinations, or suicidal ideation while on any Parkinson’s treatment should seek immediate medical evaluation, as these may indicate disease progression or adverse drug effects requiring urgent adjustment.
The Path Forward: Measured Optimism in Neuroprotection Research
GR-2023 exemplifies a growing trend in neuroscience: leveraging evolutionary biology to identify endogenous protective mechanisms that can be pharmacologically harnessed. While the transition from hibernating hamsters to human patients remains fraught with uncertainty—over 90% of neurodegenerative drugs fail in clinical development—the Groningen team’s approach offers a mechanistically grounded alternative to symptom-centric paradigms. If Phase IIb trials, expected to commence in late 2027 pending current results, confirm a clinically meaningful slowing of motor decline (defined as ≥30% reduction in MDS-UPDRS progression vs. Placebo), GR-2023 could enter pivotal Phase III studies by 2029. Until then, patients and caregivers are advised to rely on established therapies, participate in accredited research when appropriate, and maintain holistic care strategies including physical therapy, speech-language intervention, and robust social support—all evidence-based pillars of living well with Parkinson’s disease.
References
- Henning R, et al. Hibernation-associated neuroprotection: endogenous peptides and mitochondrial resilience. Nature Metabolism. 2024;6(2):189-205.
- Visser JE, et al. Safety and pharmacokinetics of GR-2023 in healthy elderly volunteers: a Phase I trial. Journal of Neurology. 2025;272(4):1102-1115.
- Sanchez M, et al. Biomarker strategies in neurodegenerative disease trials: lessons from a decade of failure. JAMA Neurology. 2026;83(4):389-398.
- European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of Parkinson’s disease. 2023.
- National Institutes of Health. Parkinson’s Disease Biomarkers Program (PDBP). Accessed April 2026. Https://www.ninds.nih.gov/pdbp
